Why RAC ASX (Race Oncology Limited) could be a good investment?
- The company has a strong pipeline of products. RAC ASX is developing a number of potential new drugs, including Zantrene, which is in Phase 2 clinical trials for the treatment of clear cell renal cell carcinoma (ccRCC). ccRCC is a type of kidney cancer that is difficult to treat and has a high mortality rate. If Zantrene is successful, it could be a major commercial success.
- The company has a experienced management team. RAC ASX's management team has a lot of experience in the pharmaceutical industry. They have a proven track record of developing and commercializing new drugs.
- The company is well-funded. RAC ASX has a strong balance sheet and has raised enough money to fund its development programs for the next few years.
Why RAC ASX (Race Oncology Limited) could be a good...
-
- There are more pages in this discussion • 5,811 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.86 |
Change
-0.015(0.80%) |
Mkt cap ! $316.8M | |||
| Open | High | Low | Value | Volume |
| $1.88 | $1.88 | $1.79 | $163.0K | 89.00K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34299 | $1.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.86 | 3635 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |